Bristol-myers Company

Hiroshi Tsukiura

Hiroshi Kawaguchi

Koji Tomita

Masataka Konishi

Takeo Miyaki

Minoru Hanada

Mitsuaki Tsunakawa

Kei-Ichi Fujisawa

Kei-ichi Fujisawa

Seikichi Kobaru

Antibiotic Bu-2659 complex, containing components A, B, C, D and E, is produced by cultivation of Streptomyces hygroscopicus Strain No. J296-21, ATCC No. 39150.

Antibiotics produced by fermentation of a novel strain of Streptomyces

A novel peptide antibiotic complex designated herein as Bu-2470 is produced by fermentation of Bacillus circulans strain G493-B6 (ATCC 31,805). Complex Bu-2470 may be separated into four bioactive peptide antibiotics designated as Bu-2470A, B.sub.1, B.sub.2a, and B.sub.2b. The complex and individual bioactive factors possess significant antimicrobial activity.

Process of producing a peptide antibiotic with Bacillus circulans

Antibiotic compounds

The known antibiotic, nocardicin, is produced by submerged aerobic cultivation of Microtetraspora caesia sp. nov. ATCC 31724 or 31725.

Fermentation process for producing nocardicins A and B

A novel antibiotic complex designated herein as Bu-2313 is produced by fermentation of Micropolyspora sp. A.T.C.C. 31295, 31296, 31297 and 31298. The complex is separated into two bioactive components, Bu-2313A and Bu-2313B, which are structurally related to the streptolydigin-tirandamycin group of antibiotics. They are active against anaerobic bacteria.

Production of antibiotics by fermentation of novel strains of

A novel antibiotic complex designated herein as Bu-2313 is produced by fermentation of Micropolyspora sp. A.T.C.C. 31295, 31296, 31297 and 31298. The complex is separated into two bioactive components, Bu-2313A and BU-2313B, which are structurally related to the streptolydigin-tirandamycin group of antibiotics. They are active against anaerobic bacteria.

A novel aminoglycoside antibiotic complex designated herein as Bu-2183 is produced by fermentation of Pseudomonas sp. strain D946-B83, A.T.C.C. 31086. Complex Bu-2183 is known to consist of at least five components, said components being herein designated Bu-2183 A, A.sub.2, B, C and D. The complex and the individual aminoglycoside components Bu-2183 A, A.sub.2, and B are found to have a broad spectrum of antibacterial activity and are especially useful in inhibiting aminoglycoside-resistant organisms including Pseudomonas species.

Antibiotic complex

A novel water-soluble basic glycopeptide antibiotic complex designated herein as Bu-2231 is produced by fermentation of a Bu-2231-producing strain of Streptoalloteichus hindustanus. Complex Bu-2231 and two of its major components designated herein as Bu-2231 A and B are found to inhibit the growth of various Gram-positive and Gram-negative and acid-fast bacteria as well as certain plant pathogens. The complex and components Bu-2231 A and B are also useful in inhibiting the growth of various tumors in rodents, for example, Walker 256 carcinosarcoma and Lewis Lung carcinoma.

Glycopeptide antibiotics Bu-2231 A and B and process for producing same

A fermentation process is disclosed for preparing the known aminoglycoside antibiotics apramycin and nebramycin factor V' by culturing Streptoalloteichus hindustanus A.T.C.C. 31217, 31218 or 31219. The so-produced nebramycin factor V' may subsequently be converted to tobramycin by base catalyzed hydrolysis.

Fermentation process for producing apramycin and nebramycin factor V'

A fermentation process for preparing capreomycin, a known antibiotic, employing a heretofore unknown microorganism is described, said microorganism being classified as a member of the genus Dactylosporangium and being herein named Dactylosporangium variesporum strain D409-5 (ATCC 31203).

Growing community of inventors

Mitaka, Japan

Hiroshi Tsukiura